According to Zhitong Finance App News, Shiyao Group (01093) announced that a randomized, multi-center, open-label clinical trial evaluating SYS 6043 (B7-H3-ADC) developed by the group to treat participants with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer has officially launched at the first center in China.
This product is an antibody-conjugated drug (ADC) targeting B7-H3 developed by the Group. The antibody part can specifically bind to the cell surface expressing B7-H3 and internalize it into the cell; its linker-drug (Linker-Drug) is a tetrapeptide ligand-conjugated topoisomerase I inhibitor, which can release small molecules of toxins to kill tumor cells through protease-specific cleavage, and exerts a bystander effect to kill surrounding tumor tissue cells without specificity. Unlike antibodies using traditional wild-type crystallizable fragments (Fc), this product can reduce lymphocyte uptake and reduce the risk of off-target toxicity, thereby improving the safety of treatment.
The Group received a drug clinical trial approval notice issued by China's State Drug Administration in July 2026. After approval, it initiated a randomized, multicenter, open-label, and positive-controlled phase III clinical trial evaluating the product compared to participants in platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.
The purpose of this phase III clinical trial is to evaluate the clinical efficacy and safety of this product and the chemotherapy regimen selected by the researchers in treating platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer participants. Currently, the recruitment and screening of test subjects is being actively promoted.